DHAP

N = 54

MINE

N = 25

Fludara + Endoxan

N = 13

CVP

N = 8

GDP

N = 5

CHOP

N = 112

P value

Age

Mean ± SD

52.53 ± 8.3

52.48 ± 8.3

44.62.62 ± 13.9

44.63 ± 13.9

48 ± 5.88

32 ± 2.24

45.55 ± 3.2

0.000

Sex

Male

Female

32 (59.3%)

22 (40.7%)

12 (48%)

13 (52%)

5 (38.5%)

8 (61.5%)

0 (0%)

8 (100%)

0 (0%)

5 (100%)

52 (46.4%)

60 (53.6%)

0.01

PS

0

1

2

5 (9.3%)

33 (61.1%)

16 (29.6%)

2 (8%)

16 (63%)

7 (28%)

3 (23.1%)

6 (46.2%)

4 (30.8%)

0 (0%)

3 (37.5%)

5 (62.5%)

4 (80%)

0 (0%)

1 (20%)

11 (9.8%)

54 (48.2%)

47 (42%)

0.000

Pathology

B cell NHL

T cell NHL

46 (58.2%)

8 (14.8%)

18 (72%)

7 (28%)

10 (76.9%)

3 (23.1%)

7 (87.5%)

1 (12.5%)

4 (80%)

1 (20%)

100 (89.3%)

12 (10.7%)

0.32

LDH

mean ± SD

295.32 ± 123.20

277.24 ± 98.39

319.92 ± 55.86

204 ± 5.3

384 ± 8.9

325.2 ± 13.2

0.162

B symptom

Positive

Negative

33 (61.1%)

21 (38.9%)

23 (92%)

2 (8%)

7 (53.8%)

6 (46.2%)

5 (62.5%)

3 (37.5%)

5 (100%)

0 (0%)

60 (53.6%)

52 (46.4%)

0.006

Stage

1A

1B

2A

2B

3A

3B

4

1 (1.9%)

1 (1.9%)

12 (22.2%)

1 (1.9%)

23 (42.6%)

12 (22.2%)

4 (7.4%)

0 (0%)

4 (16%)

5 (20%)

0 (0%)

12 (48%)

0 (0%)

4 (16%)

4 (30.8%)

0 (0%)

0 (0%)

0 (0%)

1 (7.7%)

8 (61.5%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

4 (50%)

4 (50%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

1 (20%)

4 (80%)

0 (0%)

1 (0.9%)

1 (0.9%)

23 (20.5%)

6 (5.4%)

41 (36.6%)

13 (11.6%)

27 (24.1%)

0.000

1st line

CHOP

R-CHOP

54 (100%)

0 (0%)

25 (100%)

0 (0%)

13 (100%)

0 (0%)

8 (100%)

0 (0%)

5 (100%)

0 (0%)

95 (84.8%)

17 (15.2%)

0.016

1st Response

Refractory

Relapsed

Before 1 y

After 1 y

25 (46.3%)

29 (53.7%)

28 (96.5%)

1 (3.4%)

8 (32%)

17 (30.8%)

6 (35.3%)

11 (64.7%)

9 (69.2%)

4 (30.8%)

2 (50%)

2 (50%)

0 (0%)

8 (100%)

5 (62.5%)

3 (37.5%)

4 (80%)

1 (20%)

0 (0%)

1 (100%)

67 (59.8%)

45 (40.2%)

18 (40%)

27 (60%)

0.002

0.89

IPI

Low risk

Low intermediate

High intermediate

High risk

7 (13%)

24 (44.4%)

9 (16.7%)

14 (25.9%)

9 (36%)

11 (44%)

4 (16%)

1 (4%)

3 (23.1%)

4 (30.8%)

4 (30.8%)

2 (15.4%)

1 (12.5%)

5 (62.5%)

1 (12.5%)

1 (12.5%)

4 (80%)

1 (20%)

0 (0%)

0 (0%)

26 (23.2%)

40 (35.7%)

28 (25%)

18 (16.1%)

0.05